Delivery Order SPE2DB22D3501-SPE2DB25FWU96
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a contract ceiling value of $3,425.95. This non-set-aside, competitively awarded delivery order carries firm fixed pricing and is scheduled for completion by June 3, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued under...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Esbriet 801 mg tablets (90-count) with a completion date of October 6, 2025. This is a firm fixed price, non-set-aside contract performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for supply of Esbriet 267 mg tablets (270 count) under a firm fixed price contract valued at $6,851.90. The delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, fulfills this order from its corporate office location. This delivery order is...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Esbriet (pirfenidone) 801 mg tablets in a 90-count package. This competitively awarded, firm fixed price delivery order carries a ceiling value of $3,425.95 and is scheduled for completion by July 10, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a non-set-aside award, this delivery...
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp for Esbriet 801 mg tablets (90-count supply) on July 7, 2025, with an ultimate completion date of July 28, 2025. This is a competitively awarded, firm fixed-price contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Esbriet 267 mg tablets (270-count packages) at a firm fixed price of $3,425.95, with completion scheduled for September 30, 2025. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 units, valued at $3,425.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is scheduled for completion by September 17, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 2, 2025, for the supply of Esbriet 267 mg tablets (270-count units) valued at $3,425.95, with a completion date of September 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with the agency. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency issued a delivery order on June 16, 2025, to AmerisourceBergen Drug Corp for the supply of Esbriet (pirfenidone) 267 mg tablets in a quantity of 270 tablets, with a ceiling value of $3,425.95. This order is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 9, 2025....
- The Defense Logistics Agency awarded a $3,425.95 delivery order to AmerisourceBergen Drug Corp on June 27, 2025, for 90 tablets of Esbriet 801 mg, a pharmaceutical treatment for idiopathic pulmonary fibrosis. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, was competitively awarded without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FWU96Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Esbriet 801 mg tablets (90-count units) with a ceiling value of $10,277.85. This firm fixed-price delivery order, which must be completed by September 2, 2025, represents a non-competitive set-aside award supporting federal pharmaceutical procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting Defense Health Agency and military healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999.999 billion through December 2026. The IDC enables the contractor to supply a broad range of pharmaceutical products and medical commodities across multiple therapeutic domains to support military and federal healthcare programs worldwide. Esbriet, used primarily for treating idiopathic pulmonary fibrosis, exemplifies the specialized pharmaceutical products delivered through this strategic vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 8/11/25 |